Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Stevanato Group SpA (STVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: STVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -34.4% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.19B USD | Price to earnings Ratio 40.47 | 1Y Target Price 26.88 |
Price to earnings Ratio 40.47 | 1Y Target Price 26.88 | ||
Volume (30-day avg) 373304 | Beta 0.52 | 52 Weeks Range 16.56 - 30.01 | Updated Date 04/7/2025 |
52 Weeks Range 16.56 - 30.01 | Updated Date 04/7/2025 | ||
Dividends yield (FY) 0.30% | Basic EPS (TTM) 0.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.67% | Operating Margin (TTM) 20.3% |
Management Effectiveness
Return on Assets (TTM) 4.76% | Return on Equity (TTM) 9.28% |
Valuation
Trailing PE 40.47 | Forward PE 32.36 | Enterprise Value 5555723867 | Price to Sales(TTM) 4.7 |
Enterprise Value 5555723867 | Price to Sales(TTM) 4.7 | ||
Enterprise Value to Revenue 4.56 | Enterprise Value to EBITDA 20.3 | Shares Outstanding 49604600 | Shares Floating 48805190 |
Shares Outstanding 49604600 | Shares Floating 48805190 | ||
Percent Insiders 1.68 | Percent Institutions 115.71 |
Analyst Ratings
Rating 4.27 | Target Price 26.36 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Stevanato Group SpA
Company Overview
History and Background
Stevanato Group SpA was founded in 1949 in Italy. Initially focused on glass production, it evolved to specialize in pharmaceutical packaging and drug delivery systems. It has grown through innovation and acquisitions, becoming a global leader in its field.
Core Business Areas
- Pharmaceutical Systems: Designs, manufactures, and supplies a wide range of glass primary packaging for injectable drugs, including vials, ampoules, cartridges, and syringes.
- Engineering Systems: Develops and produces machinery and equipment for the manufacturing of glass containers, inspection systems, and assembly systems for pharmaceutical products.
- Analytical Testing Services: Provides analytical testing services for the pharmaceutical industry, including material characterization, container closure integrity testing, and drug product compatibility studies.
Leadership and Structure
Franco Stevanato serves as the Executive Chairman. Franco Moro is the Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure across its business segments.
Top Products and Market Share
Key Offerings
- Glass Vials: Manufactures glass vials for pharmaceutical applications, ranging from small volume injectables to large volume solutions. Competitors include Schott, Gerresheimer, and Nipro. Market share estimated at ~20% globally (estimated and consolidated across different glass vial types).
- Syringes: Produces pre-fillable syringes for drug delivery. Competitors include Becton Dickinson (BD), Gerresheimer, and Schott. Market share estimated at ~15% globally (estimated and consolidated across different syringe types).
- Cartridges: Produces cartridges for drug delivery devices. Competitors include Gerresheimer and SCHOTT. The market share data is not readily available.
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery market is growing due to increasing demand for injectable drugs, biologics, and vaccines. Trends include pre-fillable syringes, ready-to-use components, and integrated delivery systems.
Positioning
Stevanato Group SpA is a key player due to its integrated solutions, high-quality products, and strong customer relationships. Its competitive advantage lies in its ability to offer both packaging and equipment solutions.
Total Addressable Market (TAM)
The pharmaceutical packaging market is estimated at $100+ billion. Stevanato Group SpA is well-positioned to capture a significant share of this market through innovation and expansion.
Upturn SWOT Analysis
Strengths
- Integrated solutions (packaging and equipment)
- Strong customer relationships
- Global presence
- High-quality products
- Technological innovation
Weaknesses
- Dependence on pharmaceutical industry
- Capital intensive operations
- Exposure to raw material price fluctuations
- Geographical concentration of manufacturing in Europe
Opportunities
- Growing demand for biologics and vaccines
- Expansion into emerging markets
- Development of new drug delivery technologies
- Increasing outsourcing of pharmaceutical manufacturing
Threats
- Intense competition
- Regulatory changes in the pharmaceutical industry
- Economic slowdown
- Disruptions in supply chain
Competitors and Market Share
Key Competitors
- BDX
- GGI
- DHR
Competitive Landscape
Stevanato Group SpA's strength is its integrated solutions, which are competitive against players focusing on either packaging or equipment alone. It needs to watch for larger, diversified competitors with greater financial resources.
Major Acquisitions
Balances Technology
- Year: 2023
- Acquisition Price (USD millions): 25
- Strategic Rationale: Expands capabilities in testing and inspection equipment for the pharmaceutical industry. Enhances quality control and manufacturing processes.
Growth Trajectory and Initiatives
Historical Growth: Stevanato Group SpA has shown consistent revenue growth driven by increasing demand for its products and services.
Future Projections: Analysts project continued growth for Stevanato Group SpA due to the expanding pharmaceutical market and its strong market position.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, investing in R&D, and pursuing strategic acquisitions.
Summary
Stevanato Group SpA is a strong player in the pharmaceutical packaging industry, benefiting from the increasing demand for injectable drugs and biologics. Its integrated solutions and global presence are key strengths. However, it faces competition and needs to manage raw material costs and regulatory changes effectively.
Similar Companies
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
DHR
Danaher Corporation
DHR
Danaher Corporation
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Industry Publications
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary based on data sources. Financial data requires further analysis and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stevanato Group SpA
Exchange NYSE | Headquaters Piombino Dese, PD, Italy | ||
IPO Launch date 2021-07-16 | CEO & Executive Chairman Mr. Franco Stevanato | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 5521 | Website https://www.stevanatogroup.com |
Full time employees 5521 | Website https://www.stevanatogroup.com | ||
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.